SELAS GRANDE PHARMACIE DE HOUDAN : revenue, balance sheet and financial ratios

SELAS GRANDE PHARMACIE DE HOUDAN is a French company founded 20 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in HOUDAN (78550), this company of category PME shows in 2019 a revenue of 4.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELAS GRANDE PHARMACIE DE HOUDAN (SIREN 489955823)
Indicator 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C 4 395 967 € 4 424 977 € 4 150 056 € 4 183 086 €
Net income 514 252 € 468 952 € 318 777 € 297 440 € 303 495 € 289 345 € 325 606 €
EBITDA N/C N/C N/C 469 238 € 470 407 € 480 470 € 532 007 €
Net margin N/C N/C N/C 6.8% 6.9% 7.0% 7.8%

Revenue and income statement

In 2022, SELAS GRANDE PHARMACIE DE HOUDAN generates positive net income of 514 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2022: 326 k€ -> 514 k€.

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

514 252 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 188%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 30%. The balance between equity and debt is satisfactory.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

188.095%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

30.432%

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

7.5%

Solvency indicators evolution
SELAS GRANDE PHARMACIE DE HOUDAN

Sector positioning

Debt ratio
188.09 2022
2020
2021
2022
Q1: 24.52
Med: 74.72
Q3: 182.51
Average

In 2022, the debt ratio of SELAS GRANDE PHARMACIE DE... (188.09) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
30.43% 2022
2020
2021
2022
Q1: 28.54%
Med: 47.06%
Q3: 66.61%
Average

In 2022, the financial autonomy of SELAS GRANDE PHARMACIE DE... (30.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 229.37. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

229.372

Liquidity indicators evolution
SELAS GRANDE PHARMACIE DE HOUDAN

Sector positioning

Liquidity ratio
229.37 2022
2020
2021
2022
Q1: 145.17
Med: 199.48
Q3: 274.99
Good +13 pts over 3 years

In 2022, the liquidity ratio of SELAS GRANDE PHARMACIE DE... (229.37) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELAS GRANDE PHARMACIE DE HOUDAN

Positioning of SELAS GRANDE PHARMACIE DE HOUDAN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 215 transactions of similar company sales in 2022, the value of SELAS GRANDE PHARMACIE DE HOUDAN is estimated at 6 050 950 € (range 4 067 441€ - 9 075 302€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2022
215 transactions
4067k€ 6050k€ 9075k€
6 050 950 € Range: 4 067 441€ - 9 075 302€
NAF 5 année 2022

Valuation method used

Net Income Multiple
514 252 € × 11.8x = 6 050 951 €
Range: 4 067 441€ - 9 075 302€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 215 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELAS GRANDE PHARMACIE DE HOUDAN with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELAS GRANDE PHARMACIE DE HOUDAN

What is the revenue of SELAS GRANDE PHARMACIE DE HOUDAN ?

The revenue of SELAS GRANDE PHARMACIE DE HOUDAN in 2019 is 4.4 M€.

Is SELAS GRANDE PHARMACIE DE HOUDAN profitable?

Yes, SELAS GRANDE PHARMACIE DE HOUDAN generated a net profit of 514 k€ in 2022.

Where is the headquarters of SELAS GRANDE PHARMACIE DE HOUDAN ?

The headquarters of SELAS GRANDE PHARMACIE DE HOUDAN is located in HOUDAN (78550), in the department Yvelines.

Where to find the tax return of SELAS GRANDE PHARMACIE DE HOUDAN ?

The tax return of SELAS GRANDE PHARMACIE DE HOUDAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELAS GRANDE PHARMACIE DE HOUDAN operate?

SELAS GRANDE PHARMACIE DE HOUDAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.